Information Provided By: 
Fly News Breaks for September 25, 2015
TEVA, ATRS
Sep 25, 2015 | 08:37 EDT
Oppenheimer notes that Antares (ATRS) and Teva (TEVA) are awaiting an FDA decision on the companies' application for approval of their generic EpiPen drug. The firm thinks the recent controversy over drug prices could cause the FDA to grant Antares' drug an AB substitutability rating which would allow pharmacies to "freely substitute" the product for EpiPen. The firm says that this is the key issue facing the drug. It keeps a $4 price target and Outperform rating on Antares.
News For ATRS;TEVA From the Last 2 Days
There are no results for your query ATRS;TEVA
